BACKGROUND: Despite advances in early detection and therapies, cancer is still one of the most common causes of death worldwide. Since each tumor is unique, there is a need to implement personalized care and develop robust tools for monitoring treatment response to assess drug efficacy and prevent disease relapse. MAIN BODY: Recent developments in liquid biopsies have enabled real-time noninvasive monitoring of tumor burden through the detection of molecules shed by tumors in the blood. These molecules include circulating tumor nucleic acids (ctNAs), comprising cell-free DNA or RNA molecules passively and/or actively released from tumor cells. Often highlighted for their diagnostic, predictive, and prognostic potential, these biomarkers possess valuable information about tumor characteristics and evolution. While circulating tumor DNA (ctDNA) has been in the spotlight for the last decade, less is known about circulating tumor RNA (ctRNA). There are unanswered questions about why some tumors shed high amounts of ctNAs while others have undetectable levels. Also, there are gaps in our understanding of associations between tumor evolution and ctNA characteristics and shedding kinetics. In this review, we summarize current knowledge about ctNA biology and release mechanisms and put this information into the context of tumor evolution and clinical utility. CONCLUSIONS: A deeper understanding of the biology of ctDNA and ctRNA may inform the use of liquid biopsies in personalized medicine to improve cancer patient outcomes.

Department of Biochemistry and Biophysics University of California San Francisco San Francisco CA 94158 USA

Department of Laboratory Medicine University of California San Francisco 2340 Sutter Street San Francisco CA USA

Department of Urology University of California San Francisco San Francisco CA 94158 USA

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacký University and University Hospital in Olomouc Olomouc 779 00 Czech Republic

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

Khatami F, Tavangar SM. Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy. J Diabetes Metab Disord. 2018;17:19–30. doi: 10.1007/s40200-018-0334-x. PubMed DOI PMC

Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Sci. 2019;110:1148–1155. doi: 10.1111/cas.13972. PubMed DOI PMC

Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347–376. doi: 10.1007/s10555-016-9629-x. PubMed DOI PMC

Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biol Ther. 2019;20:1057–1067. doi: 10.1080/15384047.2019.1598759. PubMed DOI PMC

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–238. doi: 10.1038/nrc.2017.7. PubMed DOI

Connors D, Allen J, Alvarez JD, Boyle J, Cristofanilli M, Hiller C, Keating S, Kelloff G, Leiman L, McCormack R, et al. International liquid biopsy standardization alliance white paper. Crit Rev Oncol Hematol. 2020;156:103112. doi: 10.1016/j.critrevonc.2020.103112. PubMed DOI

Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124:345–358. doi: 10.1038/s41416-020-01047-5. PubMed DOI PMC

Alix-Panabieres C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11:858–873. doi: 10.1158/2159-8290.CD-20-1311. PubMed DOI

Neumann MHD, Bender S, Krahn T, Schlange T. ctDNA and CTCs in liquid biopsy - current status and where we need to progress. Comput Struct Biotechnol J. 2018;16:190–195. doi: 10.1016/j.csbj.2018.05.002. PubMed DOI PMC

Grabuschnig S, Bronkhorst AJ, Holdenrieder S, Rodriguez IR, Schliep KP, Schwendenwein D, Ungerer V, Sensen CW. Putative origins of cell-free DNA in humans: a review of active and passive nucleic acid release mechanisms. Int J Mol Sci. 2020;21(21):8062. doi: 10.3390/ijms21218062. PubMed DOI PMC

Angeles AK, Janke F, Bauer S, Christopoulos P, Riediger AL, Sultmann H. Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free dna in cancer. Cancers. 2021;13(22):5615. doi: 10.3390/cancers13225615. PubMed DOI PMC

Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Koike I, Inoue T. Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci. 2009;100:303–309. doi: 10.1111/j.1349-7006.2008.01021.x. PubMed DOI PMC

Anfossi S, Babayan A, Pantel K, Calin GA. Clinical utility of circulating non-coding RNAs - an update. Nat Rev Clin Oncol. 2018;15:541–563. doi: 10.1038/s41571-018-0035-x. PubMed DOI

Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11:426–437. doi: 10.1038/nrc3066. PubMed DOI

Papadopoulos N. Pathophysiology of ctDNA release into the circulation and its characteristics: what is important for clinical applications. Tumor Liquid Biopsies. 2020;215:163–180. doi: 10.1007/978-3-030-26439-0_9. PubMed DOI

Sadik N, Cruz L, Gurtner A, Rodosthenous RS, Dusoswa SA, Ziegler O, Van Solinge TS, Wei ZY, Salvador-Garicano AM, Gyorgy B, et al. Extracellular RNAs: a new awareness of old perspectives. Extracell Rna Methods Protocols. 2018;1740:1–15. PubMed PMC

Sanchez-Herrero E, Serna-Blasco R, de Lope LR, Gonzalez-Rumayor V, Romero A, Provencio M. Circulating tumor DNA as a Cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis. Front Oncol. 2022;12:943253. doi: 10.3389/fonc.2022.943253. PubMed DOI PMC

Michela B. Liquid biopsy: a family of possible diagnostic tools. Diagnostics. 2021;11(8):1391. doi: 10.3390/diagnostics11081391. PubMed DOI PMC

Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA - looking beyond the blood. Nat Rev Clin Oncol. 2022;19:600–612. doi: 10.1038/s41571-022-00660-y. PubMed DOI PMC

Oshi M, Murthy V, Takahashi H, Huyser M, Okano M, Tokumaru Y, Rashid OM, Matsuyama R, Endo I, Takabe K. Urine as a source of liquid biopsy for cancer. Cancers. 2021;13(11):2652. doi: 10.3390/cancers13112652. PubMed DOI PMC

Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–548. doi: 10.1038/nrclinonc.2017.14. PubMed DOI

Sorolla MA, Sorolla A, Parisi E, Salud A, Porcel JM. Diving into the pleural fluid: liquid biopsy for metastatic malignant pleural effusions. Cancers. 2021;13(11):2798. doi: 10.3390/cancers13112798. PubMed DOI PMC

Ponti G, Maccaferri M, Manfredini M, Micali S, Torricelli F, Milandri R, del Prete C, Ciarrocchi A, Ruini C, Benassi L, et al. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis. Clin Chim Acta. 2019;497:76–80. doi: 10.1016/j.cca.2019.07.011. PubMed DOI

Suraj S, Dhar C, Srivastava S. Circulating nucleic acids: an analysis of their occurrence in malignancies. Biomed Rep. 2017;6:8–14. doi: 10.3892/br.2016.812. PubMed DOI PMC

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, et al. Circulating tumor DNA analysis in patients with Cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol. 2018;36:1631. doi: 10.1200/JCO.2017.76.8671. PubMed DOI

van der Pol Y, Mouliere F. Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA. Cancer Cell. 2019;36:350–368. doi: 10.1016/j.ccell.2019.09.003. PubMed DOI

Baghba R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59. doi: 10.1186/s12964-020-0530-4. PubMed DOI PMC

Corbet C, Feron O. Tumour acidosis: from the passenger to the driver's seat. Nat Rev Cancer. 2017;17:577–593. doi: 10.1038/nrc.2017.77. PubMed DOI

Karsch-Bluman A, Benny O. Necrosis in the tumor microenvironment and its role in cancer recurrence. Tumor Microenviron Recent Adv. 2020;1225:85–94. PubMed

Battistelli M, Falcieri E. Apoptotic bodies: particular extracellular vesicles involved in intercellular communication. Biology (Basel) 2020;9(1):21. PubMed PMC

Udomruk S, Orrapin S, Pruksakorn D, Chaiyawat P. Size distribution of cell-free DNA in oncology. Crit Rev Oncol Hematol. 2021;166:103455. doi: 10.1016/j.critrevonc.2021.103455. PubMed DOI

Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an In Vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164:57–68. doi: 10.1016/j.cell.2015.11.050. PubMed DOI PMC

Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, Abete L, Pristauz G, Petru E, Geigl JB, et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet. 2016;48:1273–1278. doi: 10.1038/ng.3648. PubMed DOI

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921. doi: 10.1126/scitranslmed.aat4921. PubMed DOI PMC

Korn C, Scholz SR, Gimadutdinow O, Lurz R, Pingoud A, Meiss G. Interaction of DNA fragmentation factor (DFF) with DNA reveals an unprecedented mechanism for nuclease inhibition and suggests that DFF can be activated in a DNA-bound state. J Biol Chem. 2005;280:6005–6015. doi: 10.1074/jbc.M413035200. PubMed DOI

Mizuta R, Araki S, Furukawa M, Furukawa Y, Ebara S, Shiokawa D, Hayashi K, Tanuma S, Kitamura D. DNase gamma is the effector endonuclease for internucleosomal DNA fragmentation in necrosis. PLoS One. 2013;8(12):e80223. doi: 10.1371/journal.pone.0080223. PubMed DOI PMC

Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ. 2007;14:1237–1243. doi: 10.1038/sj.cdd.4402148. PubMed DOI

Li LY, Luo L, Wang XD. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature. 2001;412:95–99. doi: 10.1038/35083620. PubMed DOI

Choi JJ, Reich CF, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology. 2005;115:55–62. doi: 10.1111/j.1365-2567.2005.02130.x. PubMed DOI PMC

Zhang L, Liang YY, Li SF, Zeng FY, Meng YA, Chen ZW, Liu S, Tao YG, Yu FL. The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. Mol Cancer. 2019;18(1):36. doi: 10.1186/s12943-019-0989-z. PubMed DOI PMC

Akca H, Demiray A, Yaren A, Bir F, Koseler A, Iwakawa R, Bagci G, Yokota J. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Gene Ther. 2013;206:73–80. doi: 10.1016/j.cancergen.2013.01.005. PubMed DOI

Tormoen GW, Haley KM, Levine RL, McCarty OJT. Do circulating tumor cells play a role in coagulation and thrombosis? Front Oncol. 2012;2:115. doi: 10.3389/fonc.2012.00115. PubMed DOI PMC

Chistiakov DA, Chekhonin VP. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Exp Mol Pathol. 2018;105:166–174. doi: 10.1016/j.yexmp.2018.07.007. PubMed DOI

Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015;17:209–224. doi: 10.1016/j.jmoldx.2015.02.001. PubMed DOI PMC

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472–484. doi: 10.1038/nrclinonc.2013.110. PubMed DOI

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang YX, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094. PubMed DOI PMC

Schutz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, Mitchell WM, Nam RK, Narod SA. Chromosomal instability in cell-free DNA is a serum biomarker for prostate Cancer. Clin Chem. 2015;61:239–248. doi: 10.1373/clinchem.2014.226571. PubMed DOI

Bach DH, Zhang W, Sood AK. Chromosomal instability in tumor initiation and development. Cancer Res. 2019;79:3995–4002. doi: 10.1158/0008-5472.CAN-18-3235. PubMed DOI PMC

Shimizu N, Shimura T, Tanaka T. Selective elimination of acentric double minutes from cancer cells through the extrusion of micronuclei. Mutat Res Fund Mol Mech Mutagenesis. 2000;448:81–90. doi: 10.1016/S0027-5107(00)00003-8. PubMed DOI

Xu K, Ding L, Chang TC, Shao Y, Chiang J, Mulder H, Wang SG, Shaw TI, Wen J, Hover L, et al. Structure and evolution of double minutes in diagnosis and relapse brain tumors. Acta Neuropathol. 2019;137:123–137. doi: 10.1007/s00401-018-1912-1. PubMed DOI PMC

Bronkhorst AJ, Wentzel JF, Ungerer V, Peters DL, Aucamp J, de Villiers EP, Holdenrieder S, Pretorius PJ. Sequence analysis of cell-free DNA derived from cultured human bone osteosarcoma (143B) cells. Tumour Biol. 2018;40:1010428318801190. doi: 10.1177/1010428318801190. PubMed DOI

Gekara NO. DNA damage-induced immune response: micronuclei provide key platform. J Cell Biol. 2017;216:2999–3001. doi: 10.1083/jcb.201708069. PubMed DOI PMC

Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99:1763–1817. PubMed PMC

Heitzer E, Auinger L, Speicher MR. Cell-free DNA and apoptosis: how dead cells inform about the living. Trends Mol Med. 2020;26:519–528. doi: 10.1016/j.molmed.2020.01.012. PubMed DOI

Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995;146:3–15. PubMed PMC

Weerasinghe P, Buja LM. Oncosis: an important non-apoptotic mode of cell death. Exp Mol Pathol. 2012;93:302–308. doi: 10.1016/j.yexmp.2012.09.018. PubMed DOI

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25:486–541. doi: 10.1038/s41418-017-0012-4. PubMed DOI PMC

Riegman M, Bradbury MS, Overholtzer M. Population dynamics in cell death: mechanisms of propacation. Trends Cancer. 2019;5:558–568. doi: 10.1016/j.trecan.2019.07.008. PubMed DOI PMC

Green DR, Llambi F. Cell death signaling. Cold Spring Harb Perspect Biol. 2015;7(12):a006080. doi: 10.1101/cshperspect.a006080. PubMed DOI PMC

Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, Cheng H, Jin K, Ni Q, Yu X, Liu C. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1):100. doi: 10.1186/s12943-019-1029-8. PubMed DOI PMC

Della Torre L, Nebbioso A, Stunnenberg HG, Martens JHA, Carafa V, Altucci L. The role of necroptosis: biological relevance and its involvement in Cancer. Cancers. 2021;13(4):684. doi: 10.3390/cancers13040684. PubMed DOI PMC

Liu L, Li J, Ke Y, Zeng X, Gao J, Ba X, Wang R. The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis. Cell Mol Life Sci. 2022;79(1):60. doi: 10.1007/s00018-021-04109-w. PubMed DOI PMC

Huang P, Chen GW, Jin WF, Mao KJ, Wan HT, He Y. Molecular mechanisms of parthanatos and its role in diverse diseases. Int J Mol Sci. 2022;23(13):7292. doi: 10.3390/ijms23137292. PubMed DOI PMC

Peters AA, Jamaludin SYN, Yapa K, Chalmers S, Wiegmans AP, Lim HF, Milevskiy MJG, Azimi I, Davis FM, Northwood KS, et al. Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells. Oncogene. 2017;36:6490–6500. doi: 10.1038/onc.2017.234. PubMed DOI

Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J, et al. The role of pyroptosis in cancer: pro-cancer or pro-"host"? Cell Death Dis. 2019;10(9):1-13. PubMed PMC

Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, Caffarel MM, Araujo AM, Araiz M, Fernandez-Mercado M, Lawrie CH. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci. 2016;17(5):627. doi: 10.3390/ijms17050627. PubMed DOI PMC

Reich CF, Pisetsky DS. The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis. Exp Cell Res. 2009;315:760–768. doi: 10.1016/j.yexcr.2008.12.014. PubMed DOI

Crescitelli R, Lasser C, Szabo TG, Kittel A, Eldh M, Dianzani I, et al. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles. 2013;2. PubMed PMC

Cui MY, Wang HD, Yao XX, Zhang D, Xie YJ, Cui RJ, Zhang XW. Circulating microRNAs in Cancer: potential and challenge. Front Genet. 2019;10:626. doi: 10.3389/fgene.2019.00626. PubMed DOI PMC

Fish L, Zhang S, Yu JX, Culbertson B, Zhou AY, Goga A, Goodarzi H. Cancer cells exploit an orphan RNA to drive metastatic progression. Nat Med. 2018;24:1743. doi: 10.1038/s41591-018-0230-4. PubMed DOI PMC

Xu XB, Lai YY, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2019;39(1):BSR20180992. doi: 10.1042/BSR20180992. PubMed DOI PMC

Komeda T, Fukuda Y, Sando T, Kita R, Furukawa M, Nishida N, Amenomori M, Nakao K. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer. 1995;75:2214–2219. doi: 10.1002/1097-0142(19950501)75:9<2214::AID-CNCR2820750905>3.0.CO;2-X. PubMed DOI

Bronkhorst AJ, Wentzel JF, Aucamp J, van Dyk E, du Plessis L, Pretorius PJ. Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta Mol Cell Res. 2016;1863:157–165. doi: 10.1016/j.bbamcr.2015.10.022. PubMed DOI

van der Vaart M, Pretorius PJ. Circulating DNA - Its origin and fluctuation. Circul Nucleic Acids Plasma Serum V. 2008;1137:18–26. PubMed

Wang W, Kong P, Ma G, Li L, Zhu J, Xia TS, Xie H, Zhou WB, Wang S. Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines. Oncotarget. 2017;8:43180–43191. doi: 10.18632/oncotarget.17858. PubMed DOI PMC

Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:640. doi: 10.1126/science.aau6977. PubMed DOI PMC

Wang K, Zhang SL, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 2010;38:7248–7259. doi: 10.1093/nar/gkq601. PubMed DOI PMC

Aucamp J, Bronkhorst AJ, Badenhorst CPS, Pretorius PJ. The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. Biol Rev. 2018;93:1649–1683. doi: 10.1111/brv.12413. PubMed DOI

Fernando MR, Jiang C, Krzyzanowski GD, Ryan WL. New evidence that a large proportion of human blood plasma cell-free DNA is localized in exosomes. PLoS One. 2017;12(8):e0183915. doi: 10.1371/journal.pone.0183915. PubMed DOI PMC

Lazaro-Ibanez E, Sanz-Garcia A, Visakorpi T, Escobedo-Lucea C, Siljander P, Ayuso-Sacido A, Yliperttula M. Different gDNA content in the subpopulations of prostate Cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate. 2014;74:1379–1390. doi: 10.1002/pros.22853. PubMed DOI PMC

Zou WC, Lai MQ, Zhang Y, Zheng L, Xing Z, Li T, et al. Exosome release is regulated by mTORC1. Adv Sci. 2019;6(3):1801313. PubMed PMC

D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012;26:1287–1299. doi: 10.1101/gad.192351.112. PubMed DOI PMC

Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26:707–721. doi: 10.1016/j.ccell.2014.09.005. PubMed DOI PMC

Bian XJ, Xiao YT, Wu TQ, Yao MF, Du LL, Ren SC, Wang JH. Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression. Mol Cancer. 2019;18(1):50. doi: 10.1186/s12943-019-0973-7. PubMed DOI PMC

Pos O, Biro O, Szemes T, Nagy B. Circulating cell-free nucleic acids: characteristics and applications. Eur J Hum Genet. 2018;26:937–945. doi: 10.1038/s41431-018-0132-4. PubMed DOI PMC

Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010;123:1603–1611. doi: 10.1242/jcs.064386. PubMed DOI PMC

Riches A, Campbell E, Borger E, Powis S. Regulation of exosome release from mammary epithelial and breast cancer cells - A new regulatory pathway. Eur J Cancer. 2014;50:1025–1034. doi: 10.1016/j.ejca.2013.12.019. PubMed DOI

Kahlert C, Melo SA, Protopopov A, Tang JB, Seth S, Koch M, Zhang JH, Weitz J, Chin L, Futreal A, Kalluri R. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014;289:3869–3875. doi: 10.1074/jbc.C113.532267. PubMed DOI PMC

Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, Zheng Y, Hoshino A, Brazier H, Xiang J, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;24:766–769. doi: 10.1038/cr.2014.44. PubMed DOI PMC

Balaj L, Lessard R, Dai LX, Cho YJ, Pomeroy SL, Breakefield XO, Skog J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011;2:180. doi: 10.1038/ncomms1180. PubMed DOI PMC

Lazaro-Ibanez E, Lasser C, Shelke GV, Crescitelli R, Jang SC, Cvjetkovic A, Garcia-Rodriguez A, Lotvall J. DNA analysis of low- and high-density fractions defines heterogeneous subpopulations of small extracellular vesicles based on their DNA cargo and topology. J Extracell Vesicles. 2019;8(1):1656993. doi: 10.1080/20013078.2019.1656993. PubMed DOI PMC

Guescini M, Genedani S, Stocchi V, Agnati LF. Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J Neural Transm. 2010;117:1–4. doi: 10.1007/s00702-009-0288-8. PubMed DOI

Lee TH, D'Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular 'debris'. Semin Immunopathol. 2011;33:455–467. doi: 10.1007/s00281-011-0250-3. PubMed DOI

Witwer KW, Goberdhan DCI, O'Driscoll L, Thery C, Welsh JA, Blenkiron C, Buzas EI, Di Vizio D, Erdbrugger U, Falcon-Perez JM, et al. Updating MISEV: evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles. 2021;10(14):e12182. doi: 10.1002/jev2.12182. PubMed DOI PMC

Qiu Y, Li PY, Zhang ZP, Wu MH. Insights into exosomal non-coding RNAs sorting mechanism and clinical application. Front Oncol. 2021;11:664904. doi: 10.3389/fonc.2021.664904. PubMed DOI PMC

Speicher MR, Pantel K. Tumor signatures in the blood. Nat Biotechnol. 2014;32:441–443. doi: 10.1038/nbt.2897. PubMed DOI

Meehan B, Rak J, Di Vizio D. Oncosomes - large and small: what are they, where they came from? J Extracell Vesicles. 2016;5:33109. doi: 10.3402/jev.v5.33109. PubMed DOI PMC

Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, Liebler DC, Ping J, Liu Q, Evans R, et al. Reassessment of exosome composition. Cell. 2019;177:428. doi: 10.1016/j.cell.2019.02.029. PubMed DOI PMC

Liangsupree T, Multia E, Riekkola ML. Modern isolation and separation techniques for extracellular vesicles. J Chromatogr A. 2021;1636:461773. doi: 10.1016/j.chroma.2020.461773. PubMed DOI

Veerman RE, Teeuwen L, Czarnewski P, Akpinar GG, Sandberg A, Cao XF, Pernemalm M, Orre LM, Gabrielsson S, Eldh M. Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular origin. J Extracell Vesicles. 2021;10(9):e12128. doi: 10.1002/jev2.12128. PubMed DOI PMC

Vagner T, Spinelli C, Minciacchi VR, Balaj L, Zandian M, Conley A, Zijlstra A, Freeman MR, Demichelis F, De S, et al. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018;7(1):1505403. doi: 10.1080/20013078.2018.1505403. PubMed DOI PMC

Clancy JW, Sedgwick A, Rosse C, Muralidharan-Chari V, Raposo G, Method M, Chavrier P, D'Souza-Schorey C. Regulated delivery of molecular cargo to invasive tumour-derived microvesicles. Nat Commun. 2015;6:6919. doi: 10.1038/ncomms7919. PubMed DOI PMC

Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G, D'Souza-Schorey C. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol. 2009;19:1875–1885. doi: 10.1016/j.cub.2009.09.059. PubMed DOI PMC

Moller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020;20:697–709. doi: 10.1038/s41568-020-00299-w. PubMed DOI

McKenzie AJ, Hoshino D, Hong NH, Cha DJ, Franklin JL, Coffey RJ, Patton JG, Weaver AM. KRAS-MEK signaling controls Ago2 sorting into exosomes. Cell Rep. 2016;15:978–987. doi: 10.1016/j.celrep.2016.03.085. PubMed DOI PMC

Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, Perez-Hernandez D, Vazquez J, Martin-Cofreces N, Martinez-Herrera DJ, Pascual-Montano A, Mittelbrunn M, Sanchez-Madrid F. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013;4:2980. doi: 10.1038/ncomms3980. PubMed DOI PMC

Groot M, Lee H. Sorting mechanisms for microRNAs into extracellular vesicles and their associated diseases. Cells. 2020;9(4):1044. doi: 10.3390/cells9041044. PubMed DOI PMC

Villarroya-Beltri C, Baixauli F, Gutierrez-Vazquez C, Sanchez-Madrid F, Mittelbrunn M. Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014;28:3–13. doi: 10.1016/j.semcancer.2014.04.009. PubMed DOI PMC

Bolukbasi MF, Mizrak A, Ozdener GB, Madlener S, Strobel T, Erkan EP, Fan JB, Breakefield XO, Saydam O. miR-1289 and "Zipcode"-like sequence enrich mRNAs in microvesicles. Mol Ther Nucleic Acids. 2012;1(2):e10. doi: 10.1038/mtna.2011.2. PubMed DOI PMC

Wei H, Chen Q, Lin L, Sha CL, Li TQ, Liu YQ, Yin XM, Xu YH, Chen L, Gao WJ, et al. Regulation of exosome production and cargo sorting. Int J Biol Sci. 2021;17:163–177. doi: 10.7150/ijbs.53671. PubMed DOI PMC

Su M, Xiao YH, Ma JL, Tang YY, Tian B, Zhang YQ, Li X, Wu ZN, Yang DS, Zhou Y, et al. Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers. Mol Cancer. 2019;18(1):90. doi: 10.1186/s12943-019-1002-6. PubMed DOI PMC

Karimi N, Cvjetkovic A, Jang SC, Crescitelli R, Feizi MAH, Nieuwland R, Lotvall J, Lasser C. Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins. Cell Mol Life Sci. 2018;75:2873–2886. doi: 10.1007/s00018-018-2773-4. PubMed DOI PMC

O'Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol. 2020;21:585–606. doi: 10.1038/s41580-020-0251-y. PubMed DOI PMC

Turchinovich A, Drapkina O, Tonevitsky A. Transcriptome of extracellular vesicles: state-of-the-art. Front Immunol. 2019;10:202. doi: 10.3389/fimmu.2019.00202. PubMed DOI PMC

Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223–7233. doi: 10.1093/nar/gkr254. PubMed DOI PMC

Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003–5008. doi: 10.1073/pnas.1019055108. PubMed DOI PMC

Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423–U182. doi: 10.1038/ncb2210. PubMed DOI PMC

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650. PubMed

Rostami A, Lambie M, Yu CW, Stambolic V, Waldron JN, Bratman SV. Senescence, necrosis, and apoptosis govern circulating cell-free DNA release kinetics. Cell Rep. 2020;31(13):107830. doi: 10.1016/j.celrep.2020.107830. PubMed DOI

Mair R, Mouliere F, Smith CG, Chandrananda D, Gale D, Marass F, Tsui DWY, Massie CE, Wright AJ, Watts C, et al. Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models. Cancer Res. 2019;79:220–230. doi: 10.1158/0008-5472.CAN-18-0074. PubMed DOI PMC

Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A. Cellular senescence: aging, cancer, and injury. Physiol Rev. 2019;99:1047–1078. doi: 10.1152/physrev.00020.2018. PubMed DOI

Cortese R, Almendros I, Wang Y, Gozal D. Tumor circulating DNA profiling in xenografted mice exposed to intermittent hypoxia. Oncotarget. 2015;6:556–569. doi: 10.18632/oncotarget.2785. PubMed DOI PMC

Otandault A, Abraham JD, Dache ZA, Khalyfa A, Jariel-Encontre I, Forne T, Prevostel C, Chouaib S, Gozal D, Thierry AR. Hypoxia differently modulates the release of mitochondrial and nuclear DNA. Br J Cancer. 2020;122:715–725. doi: 10.1038/s41416-019-0716-y. PubMed DOI PMC

Ichim G, Tait SWG. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016;16:539–548. doi: 10.1038/nrc.2016.58. PubMed DOI

Fogarty CE, Bergmann A. Killers creating new life: caspases drive apoptosis-induced proliferation in tissue repair and disease. Cell Death Differ. 2017;24:1390–1400. doi: 10.1038/cdd.2017.47. PubMed DOI PMC

Gregory CD, Paterson M. An apoptosis-driven 'onco-regenerative niche': roles of tumour-associated macrophages and extracellular vesicles. Philos Trans R Soc B Biol Sci. 2018;372(1737):20170003. PubMed PMC

Bayraktar R, Van Roosbroeck K, Calin GA. Cell-to-cell communication: microRNAs as hormones. Mol Oncol. 2017;11:1673–1686. doi: 10.1002/1878-0261.12144. PubMed DOI PMC

Yaacoub K, Pedeux R, Tarte K, Guillaudeux T. Role of the tumor microenvironment in regulating apoptosis and cancer progression. Cancer Lett. 2016;378:150–159. doi: 10.1016/j.canlet.2016.05.012. PubMed DOI

Jounai N, Kobiyama K, Takeshita F, Ishii KJ. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front Cell Infect Microbiol. 2013;2:168. PubMed PMC

Mao XW, Zhang Z, Zheng XX, Xie FF, Duan FD, Jiang LY, Chuai S, Han HZ, Han BH, Sun JY. Capture-based targeted targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung Cancer. J Thorac Oncol. 2017;12:663–672. doi: 10.1016/j.jtho.2016.11.2235. PubMed DOI

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595:432. doi: 10.1038/s41586-021-03642-9. PubMed DOI

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–990. doi: 10.1038/nm.1789. PubMed DOI PMC

Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. doi: 10.1016/j.bdq.2019.100087. PubMed DOI PMC

Khier S, Lohan L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sc OA. 2018;4(4):FSO295. doi: 10.4155/fsoa-2017-0140. PubMed DOI PMC

Leung F, Kulasingam V, Diamandis EP, Hoon DSB, Kinzler K, Pantel K, Alix-Panabieres C. Circulating tumor DNA as a Cancer biomarker: fact or fiction? Clin Chem. 2016;62:1054–1060. doi: 10.1373/clinchem.2016.260331. PubMed DOI PMC

Meng W, Paunel-Goerguelue A, Flohe S, Witte I, Schaedel-Hoepfner M, Windolf J, Loegters TT. Deoxyribonuclease is a potential counter regulator of aberrant neutrophil extracellular traps formation after major trauma. Mediat Inflamm. 2012;2012:149560. doi: 10.1155/2012/149560. PubMed DOI PMC

Chan KCA, Zhang J, Chan ATC, Lei KIK, Leung SF, Chan LYS, Chow KCK, Lo YMD. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 2003;63:2028–2032. PubMed

Jiang PY, Chan CWM, Chan KCA, Cheng SH, Wong J, Wong VWS, Wong GLH, Chan SL, Mok TSK, Chan HLY, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015;112:E1317–E1325. doi: 10.1073/pnas.1500076112. PubMed DOI PMC

Sanchez C, Snyder MW, Tanos R, Shendure J, Thierry AR. New insights into structural features and optimal detection of circulating tumor DNA determined by single-strand DNA analysis. NPJ Genom Med. 2018;3:31. doi: 10.1038/s41525-018-0069-0. PubMed DOI PMC

Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, Gligorich KM, Rostomily RC, Bronner MP, Shendure J. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12(7):e1006162. doi: 10.1371/journal.pgen.1006162. PubMed DOI PMC

Thomas MP, Liu X, Whangbo J, McCrossan G, Sanborn KB, Basar E, Walch M, Lieberman J. Apoptosis triggers specific, rapid, and global mRNA decay with 3 ' uridylated intermediates degraded by DIS3L2. Cell Rep. 2015;11:1079–1089. doi: 10.1016/j.celrep.2015.04.026. PubMed DOI PMC

Liu X, Fu R, Pan YD, Meza-Sosa KF, Zhang ZB, Lieberman J. PNPT1 release from mitochondria during apoptosis triggers decay of poly(A) RNAs. Cell. 2018;174:187. doi: 10.1016/j.cell.2018.04.017. PubMed DOI

Yuan TZ, Huang XY, Woodcock M, Du MJ, Dittmar R, Wang Y, Tsai S, Kohli M, Boardman L, Patel T, Wang L. Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep. 2016;6:19413. doi: 10.1038/srep19413. PubMed DOI PMC

Yang AC, Shao TJ, Bofill-De Ros X, Lian CJ, Villanueva P, Dai LS, Gu S. AGO-bound mature miRNAs are oligouridylated by TUTs and subsequently degraded by DIS3L2. Nat Commun. 2020;11(1):2765. doi: 10.1038/s41467-020-16533-w. PubMed DOI PMC

Ayupe AC, Reis EM. Evaluating the stability of mRNAs and noncoding RNAs. Enhancer Rnas Methods Protocols. 2017;1468:139–153. doi: 10.1007/978-1-4939-4035-6_11. PubMed DOI

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–10518. doi: 10.1073/pnas.0804549105. PubMed DOI PMC

Choi H, Lee DS. Illuminating the physiology of extracellular vesicles. Stem Cell Res Ther. 2016;7(1):55. doi: 10.1186/s13287-016-0316-1. PubMed DOI PMC

Nishida-Aoki N, Tominaga N, Takeshita F, Sonoda H, Yoshioka Y, Ochiya T. Disruption of circulating extracellular vesicles as a novel therapeutic strategy against Cancer metastasis. Mol Ther. 2017;25:181–191. doi: 10.1016/j.ymthe.2016.10.009. PubMed DOI PMC

Matsumoto A, Takahashi Y, Nishikawa M, Sano K, Morishita M, Charoenviriyakul C, Saji H, Takakura Y. Role of phosphatidylserine-derived negative surface charges in the recognition and uptake of intravenously injected B16BL6-derived exosomes by macrophages. J Pharm Sci. 2017;106:168–175. doi: 10.1016/j.xphs.2016.07.022. PubMed DOI

Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, et al. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. NPJ Breast Cancer. 2021;7(1):32. doi: 10.1038/s41523-021-00239-3. PubMed DOI PMC

Corcoran RB, Chabner BA. Application of cell-free DNA analysis to Cancer treatment. N Engl J Med. 2018;379:1754–1765. doi: 10.1056/NEJMra1706174. PubMed DOI

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446. doi: 10.1038/nature22364. PubMed DOI PMC

Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32:229–239. doi: 10.1016/j.annonc.2020.11.007. PubMed DOI PMC

Avanzini S, Kurtz DM, Chabon JJ, Moding EJ, Hori SS, Gambhir SS, Alizadeh AA, Diehn M, Reiter JG. A mathematical model of ctDNA shedding predicts tumor detection size. Sci Adv. 2020;6(50):eabc4308. doi: 10.1126/sciadv.abc4308. PubMed DOI PMC

Garcia-Olmo DC, Samos J, Picazo MG, Asensio AI, Toboso I, Garcia-Olmo D. Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Lett. 2008;272:133–140. doi: 10.1016/j.canlet.2008.07.003. PubMed DOI

El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, et al. Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal Cancer patient management care. Clin Cancer Res. 2016;22:3067–3077. doi: 10.1158/1078-0432.CCR-15-0297. PubMed DOI

Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bo TH, Oyan AM, Trovik J, Kalland KH, Jonassen I, Salvesen HB, et al. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget. 2015;6:39676–39691. doi: 10.18632/oncotarget.5344. PubMed DOI PMC

Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, Schmidt CM, Yip-Schneider MT, Allen PJ, Schattner M, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A. 2017;114:10202–10207. doi: 10.1073/pnas.1704961114. PubMed DOI PMC

Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, Pantano F, Dell'Aquila E, Anesi C, Silvestris N, et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples. J Exp Clin Cancer Res. 2020;39(1):95. doi: 10.1186/s13046-020-01601-2. PubMed DOI PMC

Margue C, Reinsbach S, Philippidou D, Beaume N, Walters C, Schneider JG, Nashan D, Behrmann I, Kreis S. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget. 2015;6:12110–12127. doi: 10.18632/oncotarget.3661. PubMed DOI PMC

Song TY, Long M, Zhao HX, Zou MW, Fan HJ, Liu Y, Geng CL, Song MF, Liu YF, Chen JY, et al. Tumor evolution selectively inactivates the core microRNA machinery for immune evasion. Nat Commun. 2021;12(1):7003. doi: 10.1038/s41467-021-27331-3. PubMed DOI PMC

Vannini I, Fanini F, Fabbri M. Emerging roles of microRNAs in cancer. Curr Opin Genet Dev. 2018;48:128–133. doi: 10.1016/j.gde.2018.01.001. PubMed DOI PMC

Da M, Jiang H, Xie YY, Jin WL, Han SW. the biological roles of exosomal long non-coding RNAs in Cancers. Onco Ther. 2021;14:271–287. doi: 10.2147/OTT.S281175. PubMed DOI PMC

Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17:47–62. doi: 10.1038/nrg.2015.10. PubMed DOI

Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458:223–227. doi: 10.1038/nature07672. PubMed DOI PMC

Dong L, Lin WR, Qi P, Xu MD, Wu XB, Ni SJ, Huang D, Weng WW, Tan C, Sheng WQ, et al. Circulating long RNAs in serum extracellular vesicles: their characterization and potential application as biomarkers for diagnosis of colorectal Cancer. Cancer Epidemiol Biomark Prev. 2016;25:1158–1166. doi: 10.1158/1055-9965.EPI-16-0006. PubMed DOI

Dragomir M, Chen BQ, Calin GA. Exosomal lncRNAs as new players in cell-to-cell communication. Transl Cancer Res. 2018;7:S243–S252. doi: 10.21037/tcr.2017.10.46. PubMed DOI PMC

Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in Cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30:836–848. doi: 10.1016/j.ccell.2016.10.009. PubMed DOI PMC

Pereira B, Chen CT, Goyal L, Walmsley C, Pinto CJ, Baiev I, Allen R, Henderson L, Saha S, Reyes S, et al. Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. Nat Commun. 2021;12(1):3199. doi: 10.1038/s41467-021-23394-4. PubMed DOI PMC

Tan CRC, Zhou L, El-Deiry WS. Circulating tumor cells versus circulating tumor DNA in colorectal cancer: pros and cons. Current Colorectal Cancer Reports. 2016;12:151–161. doi: 10.1007/s11888-016-0320-y. PubMed DOI PMC

Freidin MB, Freydina DV, Leung M, Fernandez AM, Nicholson AG, Lim E. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem. 2015;61:1299–1304. doi: 10.1373/clinchem.2015.242453. PubMed DOI

Moon SM, Kim JH, Kim SK, Kim S, Kwon HJ, Bae JS, Lee S, Lee HS, Choi MY, Jeon BH, et al. Clinical utility of combined circulating tumor cell and circulating tumor DNA assays for diagnosis of primary lung Cancer. Anticancer Res. 2020;40:3435–3444. doi: 10.21873/anticanres.14329. PubMed DOI

Li RY, Liang ZY. Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response. Chin Med J. 2020;133:2476–2485. doi: 10.1097/CM9.0000000000001097. PubMed DOI PMC

Herbreteau G, Vallee A, Charpentier S, Normanno N, Hofman P, Denis MG. Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. J Thorac Dis. 2019;11:S113–S126. doi: 10.21037/jtd.2018.12.18. PubMed DOI PMC

Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic Cancer. Gastroenterology. 2019;156:108. doi: 10.1053/j.gastro.2018.09.022. PubMed DOI PMC

Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) J Immunother Cancer. 2021;9(3):e001504. doi: 10.1136/jitc-2020-001504. PubMed DOI PMC

Pascual J, Attard G, Bidard F-C, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group. Ann Oncol. 2022;33(8):750-68. PubMed

Murugesan K, Hogan CA, Palmer Z, Reeve B, Theron G, Andama A, Somoskovi A, Steadman A, Madan D, Andrews J, et al. Investigation of preanalytical variables impacting pathogen cell-free DNA in blood and urine. J Clin Microbiol. 2019;57(11):e00782–e00719. doi: 10.1128/JCM.00782-19. PubMed DOI PMC

Cho MS, Park CH, Lee S, Park HS. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation. PLoS One. 2020;15(3):e0230622. PubMed PMC

Roschewski M, Staudt LM, Wilson WH. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood. 2016;127:3127–3132. doi: 10.1182/blood-2016-03-635219. PubMed DOI PMC

Ahlborn LB, Ostrup O. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA. APMIS. 2019;127:329–336. doi: 10.1111/apm.12912. PubMed DOI

Schwarzenbach H, Alix-Panabieres C, Muller I, Letang N, Vendrell JP, Rebillard X, Pantel K. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate Cancer. Clin Cancer Res. 2009;15:1032–1038. doi: 10.1158/1078-0432.CCR-08-1910. PubMed DOI

Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010;38:6159–6175. doi: 10.1093/nar/gkq421. PubMed DOI PMC

Brown P. The Cobas (R) EGFR Mutation Test v2 assay. Future Oncol. 2016;12:451–452. doi: 10.2217/fon.15.311. PubMed DOI

Kim ST, Banks KC, Lee SH, Kim K, Park JO, Park SH, et al. Prospective feasibility study for using cell-free circulating tumor DNA-guided therapy in refractory metastatic solid Cancers: an interim analysis. JCO Precis Oncol. 2017;1:1-15. PubMed PMC

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast Cancer. N Engl J Med. 2019;380:1929–1940. doi: 10.1056/NEJMoa1813904. PubMed DOI

Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, Fang JC, Samowitz WS, Heichman KA. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9:133. doi: 10.1186/1741-7015-9-133. PubMed DOI PMC

Stetson D, Ahmed A, Xu X, Nuttall BRB, Lubinski TJ, Johnson JH, Barrett JC, Dougherty BA. Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance. JCO Precis Oncol. 2019;3:1–9. PubMed

Board RE, Williams VS, Knight L, Shaw J, Greystoke A, Ranson M, Dive C, Blackhall FH, Hughes A. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Circul Nucleic Acids Plasma Serum V. 2008;1137:98–107. PubMed

Endzelins E, Berger A, Melne V, Bajo-Santos C, Sobolevska K, Abols A, Rodriguez M, Santare D, Rudnickiha A, Lietuvietis V, et al. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer. 2017;17(1):730. doi: 10.1186/s12885-017-3737-z. PubMed DOI PMC

Takahashi A, Okada R, Nagao K, Kawamata Y, Hanyu A, Yoshimoto S, Takasugi M, Watanabe S, Kanemaki MT, Obuse C, Hara E. Exosomes maintain cellular homeostasis by excreting harmful DNA from cells. Nat Commun. 2017;8:15287. doi: 10.1038/ncomms15287. PubMed DOI PMC

Ou HL, Hoffmann R, Gonzalez-Lopez C, Doherty GJ, Korkola JE, Munoz-Espin D. Cellular senescence in cancer: from mechanisms to detection. Mol Oncol. 2021;15:2634–2671. doi: 10.1002/1878-0261.12807. PubMed DOI PMC

Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, Javle M, Glenjen NI, Abelseth BK, Gilje B, Nordgard O. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018;16(1):300. doi: 10.1186/s12967-018-1677-2. PubMed DOI PMC

Yamamoto Y, Uemura M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, Kinouchi T, Hayashi T, Matsuzaki K, Jingushi K, et al. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. Oncotarget. 2018;9:20467–20475. doi: 10.18632/oncotarget.24943. PubMed DOI PMC

Hasenleithner SO, Speicher MR. A clinician's handbook for using ctDNA throughout the patient journey. Mol Cancer. 2022;21(1):81. doi: 10.1186/s12943-022-01551-7. PubMed DOI PMC

Paweletz CP, Lau CJ, Oxnard GR. Does testing error underlie liquid biopsy discordance? JCO Precis Oncol. 2019;3:1–3. PubMed

Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, Bortul M, Zanconati F, Nicolet S, Haegele J, et al. Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death Dis. 2019;10(7):534. doi: 10.1038/s41419-019-1770-3. PubMed DOI PMC

Qi P, Zhou X-y, Du X. Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol Cancer. 2016;15(1):39. doi: 10.1186/s12943-016-0524-4. PubMed DOI PMC

Weber DG, Johnen G, Casjens S, Bryk O, Pesch B, Jockel K-H, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes. 2013;6:518–8. PubMed PMC

He ZH, Qin XH, Zhang XL, Yi JW, Han JY. Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2018;22:46–54. PubMed

Aznaourova M, Schmerer N, Schmeck B, Schulte LN. Disease-Causing mutations and rearrangements in long non-coding RNA gene loci. Front Genet. 2020;11:527484. doi: 10.3389/fgene.2020.527484. PubMed DOI PMC

Svoboda M, Slyskova J, Schneiderova M, Makovicky P, Bielik L, Levy M, Lipska L, Hemmelova B, Kala Z, Protivankova M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 2014;35:1510–1515. doi: 10.1093/carcin/bgu055. PubMed DOI

Sui C-j, Zhou Y-m, Shen W-f, Dai B-h, Lu J-j, Zhang M-f, Yang J-m. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429. J Mol Med. 2016;94:1281–1296. doi: 10.1007/s00109-016-1442-z. PubMed DOI

Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 2018;10:59. doi: 10.1186/s13148-018-0492-1. PubMed DOI PMC

Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, Liu X, Le H, Zhang Y. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung Cancer. PLoS One. 2016;11(4):e0153046. doi: 10.1371/journal.pone.0153046. PubMed DOI PMC

Liu QY, Yu ZB, Yuan S, Xie WJ, Li CY, Hu ZY, Xiang Y, Wu N, Wu L, Bai L, Li YF. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer. Oncotarget. 2017;8:13048–13058. doi: 10.18632/oncotarget.14369. PubMed DOI PMC

Tang H, Liu Q, Liu X, Ye F, Xie X, Xie X, Wu M. Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma. J Cancer Res Ther. 2015;11:630–634. doi: 10.4103/0973-1482.146121. PubMed DOI

Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Mochon JJD, Duran I, et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 2020;151:102978. PubMed

Mathios D, Johansen JS, Cristiano S, Medina JE, Phallen J, Larsen KR, Bruhm DC, Niknafs N, Ferreira L, Adleff V, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021;12(1):5060. doi: 10.1038/s41467-021-24994-w. PubMed DOI PMC

McIntosh C, Conroy L, Tjong MC, Craig T, Bayley A, Catton C, Gospodarowicz M, Helou J, Isfahanian N, Kong V, et al. Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. Nat Med. 2021;27:999. doi: 10.1038/s41591-021-01359-w. PubMed DOI

Liu ZQ, Liu L, Weng SY, Guo CG, Dang Q, Xu H, Wang LB, Lu TY, Zhang YY, Sun ZQ, Han XW. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022;13(1):816. doi: 10.1038/s41467-022-28421-6. PubMed DOI PMC